GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (STU:R3X1) » Definitions » Cash Receipts from Loans

Opus Genetics (STU:R3X1) Cash Receipts from Loans


View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Cash Receipts from Loans?

Cash Receipts from Loans only applicable to companies reporting Cash Flow from Operations in direct method.


Opus Genetics Business Description

Traded in Other Exchanges
Address
8 Davis Drive, Suite 220, Durham, NC, USA, 27709
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.